Industry News
Victoria Fellowship winner works on relaxin
Victoria Fellowship winner Daniel Scott will be using his prize money to spend some time at Stanford University in the US working on an inhibitor of pregnancy hormone relaxin. [ + ]
Alchemia establishes level 1 ADR program
Brisbane biotech Alchemia (ASX: ACL) has taken the first step towards a NASDAQ listing, announcing it will be establishing a Level One American Depositary Receipt (ADR) program in coming months. [ + ]
Looking for drugs amongst exotic peptides
In the realm of the proteome, it’s shape rather than size that matters. Perth-based drug-discovery biotech Phylogica believes it has just about every possible molecular contingency covered. [ + ]
Acrux to deliver a September IPO
Drug delivery company Acrux is preparing for a late September float on the Australian Stock Exchange after filing its prospectus for an AUD$30 million IPO with the Australian Securities and Investment Commission yesterday. [ + ]
Cash-poor Prima plans for agreements
Despite capital raisings and exercise of options totalling $7.3 million during the year, Prima Biomed (ASX: PRR) is down to a cash balance of $2.8 million after posting a net loss of $4.9 million for the 2003-2004 financial year. [ + ]
Ventracor posts $16m loss
Ventracor (ASX: VCR) yesterday posted an AUD$15.9 million net loss for the 2003-2004 financial year, up 70 per cent from last year's $9.4 million. [ + ]
Malaria: the wizard of oz
The ancient Chinese pharmacopoeia has bequeathed Western medicine a dragon-slaying drug that promises to save the lives of up to two million people a year – half of them children under the age of two – in regions of the world haunted by drug-resistant strains of malaria. [ + ]
Meditech boosted by Phase II results
With all patients in the first stage of its Phase II HyCamp clinical trial escaping the gastrointestinal side-effects normally associated with standard colon cancer treatment irinotecan, Meditech (ASX:MTR) has announced it will forge ahead with second stage of its trial. [ + ]
NZ bio calls for $650m biotech bridge; SA govt approves incubator
New Zealand’s biotechnology industry wants the NZ government to establish a NZ$650-660 million, taxpayer-funded bridge between the nation’s research laboratories and its biotech business sector. [ + ]
Australia lagging as GM industry grows
One of the founders of Australia’s leading private wheat-breeding company has delivered a bleak prognosis for the commercial future of GM crops in Australia. [ + ]
Somnomed placement closes early and oversubscribed
Sleep apnoea and snoring device company Somnomed has closed its oversubscribed placement a week early, ahead of an expected float on August 27, 2004. [ + ]
Nugent wins Victoria Prize
The Victoria Prize was awarded today to Melbourne University physicist Prof Keith Nugent for his work on phase imaging and X-ray optics. [ + ]
How to surf the GM-testing wave
If there’s money in muck, there’s also moolah in mania, according to molecular geneticist Dr Roland Toder, who built the Freiburg-based biotech company GeneScan Europe into the world’s leading gene-testing company for food and food ingredients. [ + ]
Biota moves US research to Australia
Biota (ASX: BTA) will relocate its US research operations to its new facilities in Melbourne in a bid to save costs. [ + ]
Chemeq confirms details of $50m capital raising
Chemeq (ASX: CMQ) has confirmed that its capital raising will include a placement of around AUD$10 million to institutions and sophisticated investors, as well as an underwritten rights offer of around $40 million to existing shareholders. [ + ]
